CONTENTS:
- Offering the best death possible: supporting people using substances at the end of life [Editorial]. Galvani S., p. 391-392.
- Utilizing the commodity purchase task to evaluate behavioral economic demand for illicit substances: a review and meta-analysis. Strickland J.C., Campbell E.M., Lile J.A., Stoops W.W., p. 393-406.
- Commentary on Strickland et al. (2020): Do commodity purchase tasks provide clinically meaningful indices of motivation to consume drugs? Murphy J.G., p. 407-408.
- Fetal alcohol spectrum disorder: a systematic review of the cost of and savings from prevention in the United States and Canada. Greenmyer J.R., Popova S., Klug M.G., Burd L., p. 409-417.
- Long-term effects of youth unemployment on alcohol-related morbidity. Thern E., Ramstedt M., Svensson J., p. 418-425.
- Identifying an accurate self-reported screening tool for alcohol use disorder: evidence from a Swiss, male population-based assessment. Baggio S., Trachsel B., Rousson V., Rothen S., Studer J., Marmet S., et al., p. 426-436.
- Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Morozova O., Crawford F.W., Cohen T., Paltiel A.D., Altice F.L., p. 437-450.
- Codeine use and harms in Australia: evaluating the effects of re-scheduling. Cairns R., Schaffer A.L., Brown J.A., Pearson S.A., Buckley N.A., p. 451-459.
- Commentary on Cairns et al. (2020): Codeine rescheduling-where to from here? Nielsen S., p. 460-461.
- A comparison of trends in wastewater-based data and traditional epidemiological indicators of stimulant consumption in three locations. Goulding N., Hickman M., Reid M., Amundsen E.J., Baz-Lomba J.A., O'Brien J.W., et al., p. 462-472.
- Trends in gamma-hydroxybutyrate-related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia. Arunogiri S., Moayeri F., Crossin R., Killian J.J., Smith K., Scott D., et al., p. 473-479.
- Commentary on Arunogiri et al. (2020): Findings from surveillance of patterns of drug use and related harms need careful interpretation, promotion and response. Dietze P., Horyniak D., p. 480-481.
- Cannabis use, depression and self-harm: phenotypic and genetic relationships. Hodgson K., Coleman J.R.I., Hagenaars S.P., Purves K.L., Glanville K., Choi S.W., et al., p. 482-492.
- Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014. Burke L.G., Zhou X., Boyle K.L., Orav E.J., Bernson D., Hood M.E., et al., p. 493-504.
- Commentary on Burke et al. (2020): Safer and less-frequent opioid prescribing are both essential for US public health. Humphreys K., p. 505-506.
- Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Li J., Hajek P., Pesola F., Wu Q., Phillips-Waller A., Przulj D., et al., p. 507-517.
- Understanding decisions to use e-cigarettes or behavioural support to quit tobacco: a qualitative study of current and ex-smokers and stop smoking service staff. Hartwell G., Egan M., Petticrew M., p. 518-526.
- Challenges to implementing the WHO Framework Convention on Tobacco Control guidelines on tobacco cessation treatment: a qualitative analysis. Shelley D.R., Kyriakos C., McNeill A., Murray R., Nilan K., Sherman S.E., et al., p. 527-533.
- Cost-effectiveness and cost-utility analysis of a work-place smoking cessation intervention with and without financial incentives. van den Brand F.A., Nagelhout G.E., Winkens B., Chavannes N.H., van Schayck O.C.P., Evers S., p. 534-545.
- Functional and structural social support, substance use and sexual orientation from a nationally representative sample of US adults. Kahle E.M., Veliz P., McCabe S.E., Boyd C.J., p. 546-558.
- Heavy cannabis use, dependence and the brain: a clinical perspective. Kroon E., Kuhns L., Hoch E., Cousijn J., p. 559-572.
- Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). Barré T., Marcellin F., Di Beo V., Delorme J., Rojas Rojas T., Mathurin P., et al., p. 573-582.
- Commentary on Barré et al. (2020): Identifying remaining barriers to hepatitis C treatment in the DAA era. Sacks-Davis R., van Santen D.K., Doyle J.S., p. 583-584.
- Response to Serrano-Alarcon et al. (2019): Tobacco control policy and smokers aged 65 years and older. Kleykamp B.A., p. 585-586.
- Retiring from smoking: Reply to Kleykamp (2019). Serrano-Alarcon M., Kunst A.E., Bosdriesz J.R., Perelman J., p. 586-587.
- Cannabis vaping and health: regulatory considerations. Borodovsky J.T., Cavazos-Rehg P.A., Bierut L.J., Grucza R.A., p. 587-588.
- Cannabis, crashes and blood: challenges for observational research. Beckson M., Jones A.W., Els C., Hagtvedt R., p. 589-590.
- Reply to Beckson et al. (2019): Cannabis, crashes, and blood: challenges for observational research. Brubacher J.R., MacDonald S., Mann R., Eppler J., Asbridge M., Chan H., p. 590-591.